Trials for Cerebellar Ataxias Trials for Cerebellar Ataxias
Contemporary Clinical Neuroscience

Trials for Cerebellar Ataxias

From Cellular Models to Human Therapies

    • USD 189.99
    • USD 189.99

Descripción editorial

Despite the critical importance of the cerebellum in brain functions, the scientific community still lacks effective treatments for most cerebellar ataxias. This book provides a link between the pathogenesis and therapies of cerebellar ataxias while also providing a comprehensive assessment of the preclinical and clinical trials dedicated to cerebellar ataxias over the past 20 years of progress. This is the first book fully dedicated to the trials and therapies of these disorders. It is a truly authoritative and comprehensive reference and comes at a time of major advances in genetic tools and neuroimaging assessments. The coverage begins by laying a foundation of the basic science of the cerebellum and ataxias, proceeds to discuss biomarkers and the tools of trials, offers guidelines on conducting trials, and then explores the full range of therapeutics and their trials, including gene therapy and cell transplantation. The authors are top experts on cerebellar research and the contributing authors have all made seminal contributions in the field.

GÉNERO
Ciencia y naturaleza
PUBLICADO
2023
29 de mayo
IDIOMA
EN
Inglés
EXTENSIÓN
738
Páginas
EDITORIAL
Springer International Publishing
VENDEDOR
Springer Nature B.V.
TAMAÑO
40.2
MB

Otros libros de esta serie

Mechanisms and Emerging Therapies in Tremor Disorders Mechanisms and Emerging Therapies in Tremor Disorders
2023
Biomarkers for Huntington's Disease Biomarkers for Huntington's Disease
2023
Neurobiological and Psychological Aspects of Brain Recovery Neurobiological and Psychological Aspects of Brain Recovery
2023
Development of the Cerebellum from Molecular Aspects to Diseases Development of the Cerebellum from Molecular Aspects to Diseases
2023
Cerebellum as a CNS Hub Cerebellum as a CNS Hub
2021
New Rapid-acting Antidepressants New Rapid-acting Antidepressants
2021